<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05095103</url>
  </required_header>
  <id_info>
    <org_study_id>NHS001843</org_study_id>
    <nct_id>NCT05095103</nct_id>
  </id_info>
  <brief_title>Immune Profiles in Myasthenia Gravis</brief_title>
  <official_title>Comparison of Lymphocyte Subset, Cytokine and Complement Profiles in Myasthenia Gravis of Different Severity, Disease Time-points, and Treatment History</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manchester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Salford Royal NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Walton Centre NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oxford University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College London Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Birmingham NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imperial College Healthcare NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Newcastle-upon-Tyne Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King's College Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nottingham University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Southampton NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardiff University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Manchester</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to better describe the immune profile in myasthenia gravis (MG),&#xD;
      including lymphocyte subset, cytokine and complement profiles; how they differ between&#xD;
      patients of different severity, at times of disease exacerbation, and with different&#xD;
      immunosuppressive treatments. The investigators hope to build a clearer picture of how&#xD;
      different immune measures vary in MG, contributing to the understanding of the&#xD;
      patho[physiology of the disease, and working towards a biomarker that might help clinicians&#xD;
      optimise an individual's treatment.&#xD;
&#xD;
      the investigators aim to take into account the heterogeneity of MG by taking into account age&#xD;
      of onset of MG (early vs late onset) and focussing on acetylcholine receptor antibody (AChR)&#xD;
      positive, non-thymomatous MG aged 18-80.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to confirm and refine the knowledge around these changes in the immune&#xD;
      profile, including lymphocyte subsets, and complement analysis, between different subgroups&#xD;
      of patients with MG of different severity, different levels of immunosuppressive treatment,&#xD;
      and at different time points in the disease course, ensuring these are put into the context&#xD;
      of the patient's disease subtype (late-onset (LOMG) vs early-onset (EOMG)). This should&#xD;
      enable us to understand more about the underlying immune changes in MG, how they relate to&#xD;
      disease activity or severity, how this is impacted upon by immunosuppression, and guide us&#xD;
      towards a markers for disease severity and effective immunosuppression that could be used in&#xD;
      clinical practice, and help guide treatment decisions. One of the challenges in studying&#xD;
      patients with MG with the relatively low prevalence of the condition, meaning it can be&#xD;
      difficult to recruit large enough numbers of patients; the investigators will work with other&#xD;
      tertiary neurology centres throughout England in order to meet recruitment targets.&#xD;
&#xD;
      The research project will consist of three work streams:&#xD;
&#xD;
        1. A one-off observational comparison of the immune profile of patients with different MG&#xD;
           severity and in comparison to healthy controls.&#xD;
&#xD;
        2. A prospective observational study examining changes in lymphocyte subset, cytokine and&#xD;
           complement profiles associated with clinical exacerbation of myasthenia gravis.&#xD;
&#xD;
        3. A prospective cohort study comparing lymphocyte subset, cytokine and complement profile&#xD;
           with disease activity following B cell depletion for refractory myasthenia gravis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome work stream 1</measure>
    <time_frame>Baseline</time_frame>
    <description>Difference in CD19 count between cohorts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary outcome work stream 2</measure>
    <time_frame>Relapse within 18 months of recrutiment</time_frame>
    <description>● CD27 frequency (% of peripheral blood mononuclear cells) at clinical exacerbation of MG compared to when that patient was clinically stable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary outcome work stream 3</measure>
    <time_frame>12 months after B cell depletion</time_frame>
    <description>● CD27+ frequency (% of peripheral blood mononuclear cells) in MG patients who are symptomatic compared to those who are asymptomatic 12 months following B cell depletion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MG Composite Score</measure>
    <time_frame>Baseline, at any clinical relapse within 18 months, 3,6 months after relapse in stable groups or 4 weeks, 6 and 12 months post rituximab in refractory groups,</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MGFA - Post Intervention status</measure>
    <time_frame>Baseline, at any clinical relapse within 18 months, 3,6 months after relapse in stable groups or 4 weeks, 6 and 12 months post rituximab in refractory groups</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MG QOL-15r</measure>
    <time_frame>Baseline, at any clinical relapse within 18 months, 3,6 months after relapse in stable groups or 4 weeks, 6 and 12 months post rituximab in refractory groups</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acetylcholine receptor antibody titre</measure>
    <time_frame>Baseline, at any clinical relapse within 18 months, 3,6 months after relapse in stable groups or 4 weeks, 6 and 12 months post rituximab in refractory groups</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte Count</measure>
    <time_frame>Baseline, at any clinical relapse within 18 months, 3,6 months after relapse in stable groups or 4 weeks, 6 and 12 months post rituximab in refractory groups</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of relapses requiring hospital admission or rescue therapy</measure>
    <time_frame>Baseline, at any clinical relapse within 18 months, 3,6 months after relapse in stable groups or 4 weeks, 6 and 12 months post rituximab in refractory groups</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daily dose of prednisolone over the three months prior to review</measure>
    <time_frame>Baseline, at any clinical relapse within 18 months, 3,6 months after relapse in stable groups or 4 weeks, 6 and 12 months post rituximab in refractory groups</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">163</enrollment>
  <condition>Myasthenia Gravis</condition>
  <arm_group>
    <arm_group_label>Stable Immunosuppressed</arm_group_label>
    <description>Acetylcholine repector antibody positvie myasthenia gravis, stable for two years on prednsiolone &lt;5mg/day and azathioprine or mycophenolate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stable Non-immunosuppressed</arm_group_label>
    <description>Acetylcholine repector antibody positvie myasthenia gravis, stable for two years on ≤120mg pyridostigmine/day and no immunosuppression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Refractory</arm_group_label>
    <description>Acetylcholine repector antibody positvie myasthenia gravis, meeting the NHS England criteria for Rituximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>No autoimmune disease or current solid organ or haematological malignancy.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Acetylcholine receptor antibody positive myasthenia gravis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All participants:&#xD;
&#xD;
          -  Are able to give valid written consent&#xD;
&#xD;
          -  are aged between the ages of 18 and 80&#xD;
&#xD;
        Stable Immunosuppressed&#xD;
&#xD;
          -  Have a diagnosis of AChR positive myasthenia gravis (can be ocular, bulbar or&#xD;
             generalised)&#xD;
&#xD;
          -  MGFA Post-intervention Status MM or better with no clinical relapse for 2 years&#xD;
&#xD;
          -  On either azathioprine or MMF along with ≤5mg/day of prednisolone&#xD;
&#xD;
          -  No prednisolone dose increase or decrease in past 12 months&#xD;
&#xD;
          -  No increase in azathioprine or MMF dose for 2 years (allowing for cessation for up to&#xD;
             1 month)&#xD;
&#xD;
        Stable Non-Immunosuppressed&#xD;
&#xD;
          -  have a diagnosis of AChR positive myasthenia gravis (can be ocular, bulbar or&#xD;
             generalised)&#xD;
&#xD;
          -  MGFA Post-intervention Status MM or better on only low-dose cholinesterase inhibitors&#xD;
             (≤&lt;120 mg pyridostigmine/day) for over two years and ≤5mg/day of prednisolone for over&#xD;
             two years.&#xD;
&#xD;
          -  No prednisolone dose increase or decrease in past 12 months&#xD;
&#xD;
        Refractory&#xD;
&#xD;
          -  have a diagnosis of AChR positive myasthenia gravis (can be ocular, bulbar or&#xD;
             generalised)&#xD;
&#xD;
          -  have been deemed eligible to be refractory to standard treatment and eligible for&#xD;
             rituximab as per the NHS England criteria.&#xD;
&#xD;
        Exclusion Criteria for all participants:&#xD;
&#xD;
          -  Are unable to give valid consent&#xD;
&#xD;
          -  Co-existing autoimmune condition for which azathioprine or mycophenolate mofetil are&#xD;
             treatments (e.g. inflammatory bowel disease, rheumatoid arthritis, neuromyotonia)&#xD;
&#xD;
          -  Currently undergoing treatment for solid organ or haematological malignancy, or&#xD;
             previous thymoma&#xD;
&#xD;
          -  Clinical frailty scale ≥6&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Dodd, MBChB MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manchester</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katherine Dodd, MBChB MRCP</last_name>
    <phone>07599 072993</phone>
    <email>katherine.dodd-3@postgrad.manchester.ac.uk</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Manchester</investigator_affiliation>
    <investigator_full_name>Katherine Dodd</investigator_full_name>
    <investigator_title>Neurology Clinical Research Fellow and PhD Student</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myasthenia Gravis</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

